Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Gap Inc V.GAP


Primary Symbol: GAP

The Gap, Inc. is a specialty apparel company in America. The Company offers apparel, accessories and personal care products for women, men and children. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories and lifestyle products for men, women and children. It is an omni-channel retailer, with sales to customers both in stores and online, through Company-operated and franchise stores, websites, and third-party arrangements. Its omni-channel services, including buying online pick-up in store, order-in-store, find-in-store, and ship-from-store, as well as enhanced mobile-enabled experiences, are tailored across its collection of brands. Gap includes adult apparel and accessories, GapKids, babyGap, Gap Maternity, GapBody, and GapFit collections. Banana Republic is a premium lifestyle retailer celebrating exploration and self-expression through timeless quality, versatile fabrics, and exceptionally made womenswear, menswear, and home designs.


NYSE:GAP - Post by User

<< Previous
Bullboard Posts
Next >>
Post by indahouseon Apr 19, 2011 3:03pm
427 Views
Post# 18455363

"hotstocked" piece

"hotstocked" piece
Intriguing Drug Potential Sets Share Price Higher for PharmaGap Inc. (CVE:GAP) (PINK:PHRGF)
Contributed by: Gediminas Jasionis
Date: Apr 19, 2011
gap_chart.pngPharmaGap Inc. (CVE:GAP, GAP message board) (PINK:PHRGF) broke the established downtrend after bouncing up on a huge trading volume on Monday. The effect was caused by an announcement of positive results from in vivo preclinical testing at the Ottawa Hospital Research Institute.
The company attempts to create a peptide formulation based drug to cure ovarian cancer. The substance called GAP-107B8 proved to be able to reduce tumour burden by 19% and suppress ascites formation by 73% compared to the control group in a pre-clinical testing.
If successful the drug would pioneer the treatment of ovarian cancer as there are currently no drug based treatment for it.
Share price ended the day with a mere 5% increase in price, but it was a noticeable change in the dynamics of share price action. Trading volume was nearly 8 times the 90 day average. The similar situations happened three times over the past half a year, but this time the difference lies in related news.
pharmagap_logo.jpgSince in vivo tests were positive the drug automatically appears more trustworthy. However, traders might be jumping in too soon.
The financial situation of PharmaGap is critical:
No regular income from any source;
Liquid capital not enough to cover even one quarter's expenditures;
Liabilities top assets more than 3 times;
Additional capital always brought in through sale of more shares.
They will need more cash and thus the share price is likely to go back down after the shares offering. $12 million market cap is not supported by the underlying assets of PharmaGap and their product is of a discussable worth at the moment.
<< Previous
Bullboard Posts
Next >>